Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
The Lancet. Infectious Diseases
|
January 26, 2026
Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial
Ilse De Coster, Mohammad AbdelGhany, Eleanna Sarakinou, et al.
Human Molecular Genetics
|
January 18, 2014
A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease
Marianne R Smith, Adeela Syed, Tamas Lukacsovich, et al.
British Journal of Clinical Pharmacology
|
September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease
Sigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 9, 2026
SpyCEP dismantles neutrophil immunity via disorder-driven chemokine remodeling and GAG targeting
Rikin J Lau, Sean P Giblin, Andra Sugar, et al.
Nature Chemical Biology
|
April 8, 2015
siRNA screen identifies QPCT as a druggable target for Huntington's disease
Maria Jimenez-Sanchez, Wun Lam, Michael Hannus, et al.
Nature Medicine
|
August 8, 2025
Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting
Alexander J Keeley, Fatoumata E Camara, Edwin P Armitage, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
The Lancet. Infectious Diseases
|
January 26, 2026
Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial
Ilse De Coster, Mohammad AbdelGhany, Eleanna Sarakinou, et al.
Human Molecular Genetics
|
January 18, 2014
A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease
Marianne R Smith, Adeela Syed, Tamas Lukacsovich, et al.
British Journal of Clinical Pharmacology
|
September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease
Sigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 9, 2026
SpyCEP dismantles neutrophil immunity via disorder-driven chemokine remodeling and GAG targeting
Rikin J Lau, Sean P Giblin, Andra Sugar, et al.
Nature Chemical Biology
|
April 8, 2015
siRNA screen identifies QPCT as a druggable target for Huntington's disease
Maria Jimenez-Sanchez, Wun Lam, Michael Hannus, et al.
Nature Medicine
|
August 8, 2025
Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting
Alexander J Keeley, Fatoumata E Camara, Edwin P Armitage, et al.
Page
of 3